Potential biomarkers for the diagnosis of stroke

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 4, 2009, Pages 389-393

  Jensen, Matthew B ^a,b   Chacon, Marcus R ^a   Sattin, Justin A ^a   Levine, Ross L ^a   Vemuganti, Raghu ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Biomarker; Blood brain barrier; Diagnosis; Serum; Stroke

Indexed keywords

ALTEPLASE; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; FIBRONECTIN; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR BETA SUBUNIT; NEURON SPECIFIC ENOLASE; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

BLOOD CLOT LYSIS; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; DEATH; DIAGNOSTIC IMAGING; DISABILITY; EPIDURAL HEMATOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STROKE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; VALIDITY; VENOUS THROMBOEMBOLISM; ANIMAL; BRAIN; GENETIC MARKER; METABOLISM; REPRODUCIBILITY; THROMBOSIS; TIME; VALIDATION STUDY;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; GENETIC MARKERS; HUMANS; INFLAMMATION; REPRODUCIBILITY OF RESULTS; STROKE; THROMBOSIS; TIME FACTORS; VALIDATION STUDIES AS TOPIC;

EID: 67650321178     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.9     Document Type: Review

References (34)

1. Saver J. Proposal for a universal definition of cerebral infarction. Stroke 39(11), 3110-3115 (2008).
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581-1587 (1995).
3. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317-1329 (2008).
4. Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 282(21), 2003-2011 (1999).
5. Stead L, Gilmore R, Bellolio M, Rabinstein A, Decker W. Percutaneous clot removal devices in acute ischemic stroke: a systematic review and meta-analysis. Arch. Neurol. 65(8), 1024-1030 (2008).
6. Whiteley W, Tseng M, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 39(10), 2902-2909 (2008).
7. Ruzak-Skocir B, Trbojevic-Cepe M. Study of serum and cerebrospinal fluid enzymes in diagnosis and differential diagnosis of cerebrovascular diseases. Neurologija 39(4), 239-250 (1990).
8. Anand N, Stead L. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc. Dis. 20(4), 213-219 (2005).
9. Bigal M, Lipton R. Clinical course in migraine: conceptualizing migraine transformation. Neurology 71(11), 848-855 (2008).
10. Laskowitz D, Kasner S, Saver J et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke. The Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 40(1), 77-85 (2008).
11. Brown M, O'Brien W, Wong T et al. Neurocardiogenic effects of acute ischaemic stroke on left ventricular function. Heart Lung Circ. 17(Suppl. 3), S88-S89 (2008).
12. Peeters W, Hellings W, de Kleijn D et al. Carotid atherosclerotic plaques stabilize after stroke, insights into the natural process of atherosclerotic plaque stabilization. Arterioscler. Thromb. Vasc. Biol. 29(1), 128-133 (2008).
13. Tang Y, Lu A, Aronow B, Wagner K, Sharp F. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur. J. Neurosci. 15(12), 1937-1952 (2002).
14. Tang Y, Nee A, Lu A, Ran R, Sharp F, Blood genomic expression profile for neuronal injury. J. Cereb. Blood Flow Metab. 23(3), 310-319 (2003).
15. Xu H, Tang Y, Liu D et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab. 28(7), 1320-1328 (2008).
16. Lamers K, Vos P, Verbeek M, Rosmalen F, van Geel W, van Engelen B. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 61(3), 261-264 (2003).
17. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 28(10), 1956-1960 (1997).
18. Reynolds M, Kirchick H, Dahlen J et al. Early biomarkers of stroke. Clin. Chem. 49(10), 1733-1739 (2003).
19. Lynch J, Blessing R, White W, Grocott H, Newman M, Laskowitz D. Novel diagnostic test for acute stroke. Stroke 35(1), 57-63 (2004).
20. Dambinova S, Khounteev G, Izykenova G, Zavolokov I, Ilyukhina A, Skoromets A. Blood test detecting autoantibodies to N-methyl-[s D s]-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 49(10), 1752-1762 (2003).
21. Allard L, Burkhard P, Lescuyer P et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem. 51(11), 2043-2051 (2005).
22. Powers R, Majors A, Cerula S, Huber H, Schmidt B, Roberts J. Changes in markers of vascular injury in response to transient hyperhomocysteinemia. Metabolism, 52(4), 501-507 (2003).
23. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32(1), 133-138 (2001).
24. Arenillas J, Alvarez-Sabín J, Molina C et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 34(10), 2463-2468 (2003).
25. Leu H, Lin C, Lin W, Wu T, Chen J. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein. Chest 126(4), 1032-1039 (2004).
26. Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36(6), 1316-1329 (2005).
27. Rost N, Wolf P, Kase C et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32(11), 2575-2579 (2001).
28. Curb J, Abbott R, Rodriguez B et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107(15), 2016-2020 (2003).
29. Sotgiu S, Zanda B, Marchetti B et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol. 13(5), 505-513 (2006).
30. Kim J, Yoon S, Kim Y, Ryu J. Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 27(9), 1553-1557 (1996).
31. Fon E, Mackey A, Côté R et al. Hemostatic markers in acute transient ischemic attacks. Stroke 25(2), 282-286 (1994).
32. Mauriello A, Sangiorgi G, Palmieri G et al. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid. plaques in patients affected by transient ischemic attacks. Circulation 101(7), 744-750 (2000).
33. Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med. 118(12), 956-963 (1993).
34. Wolff V, Aleil B, Giroud M et al. Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 36(3), e17-e19 (2005).